These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

151 related items for PubMed ID: 38968525

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Intrathecal cervical analgesia for cancer pain: a 12-year follow-up study in a comprehensive cancer center.
    Dupoiron D, Bienfait F, Carvajal G, Seegers V, Douillard T, Jubier-Hamon S, Delorme T, Julienne A, Pluchon YM, Ribault N, Nader E, Lebrec N.
    Reg Anesth Pain Med; 2024 Oct 08; 49(10):757-763. PubMed ID: 37973378
    [Abstract] [Full Text] [Related]

  • 5. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
    Lin CP, Lin WY, Lin FS, Lee YS, Jeng CS, Sun WZ.
    J Formos Med Assoc; 2012 May 08; 111(5):253-7. PubMed ID: 22656395
    [Abstract] [Full Text] [Related]

  • 6. Intrathecal treatment in cancer patients unresponsive to multiple trials of systemic opioids.
    Mercadante S, Intravaia G, Villari P, Ferrera P, Riina S, David F, Mangione S.
    Clin J Pain; 2007 May 08; 23(9):793-8. PubMed ID: 18075407
    [Abstract] [Full Text] [Related]

  • 7. Multimodal intrathecal analgesia in refractory cancer pain.
    Mastenbroek TC, Kramp-Hendriks BJ, Kallewaard JW, Vonk JM.
    Scand J Pain; 2017 Jan 08; 14():39-43. PubMed ID: 28850428
    [Abstract] [Full Text] [Related]

  • 8. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).
    Smith TJ, Coyne PJ, Staats PS, Deer T, Stearns LJ, Rauck RL, Boortz-Marx RL, Buchser E, Català E, Bryce DA, Cousins M, Pool GE.
    Ann Oncol; 2005 May 08; 16(5):825-33. PubMed ID: 15817596
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Efficacy of Patient-Controlled Intravenous Analgesia with Esketamine for Herpes Zoster Associated with Breakthrough Pain.
    Tang J, Zhang E, Huang B, Fei Y, Yao M.
    Pain Physician; 2023 May 08; 26(3):299-306. PubMed ID: 37192235
    [Abstract] [Full Text] [Related]

  • 11. A cost utilization analysis of intrathecal therapy for refractory cancer pain: identifying factors associated with cost benefit.
    Brogan SE, Winter NB, Abiodun A, Safarpour R.
    Pain Med; 2013 Apr 08; 14(4):478-86. PubMed ID: 23461787
    [Abstract] [Full Text] [Related]

  • 12. Long-term intrathecal infusion of morphine in the home care of patients with advanced cancer.
    Gestin Y, Vainio A, Pégurier AM.
    Acta Anaesthesiol Scand; 1997 Jan 08; 41(1 Pt 1):12-7. PubMed ID: 9061109
    [Abstract] [Full Text] [Related]

  • 13. Intrathecal Drug Delivery Systems for Cancer Pain: An Analysis of a Prospective, Multicenter Product Surveillance Registry.
    Stearns LM, Abd-Elsayed A, Perruchoud C, Spencer R, Hammond K, Stromberg K, Weaver T.
    Anesth Analg; 2020 Feb 08; 130(2):289-297. PubMed ID: 31567325
    [Abstract] [Full Text] [Related]

  • 14. Long-Term Intrathecal Analgesia With a Wireless Analgesia Pump System in the Home Care of Patients With Advanced Cancer.
    Liu HJ, Li WY, Chen HF, Cheng ZQ, Jin Y.
    Am J Hosp Palliat Care; 2017 Mar 08; 34(2):148-153. PubMed ID: 26537661
    [Abstract] [Full Text] [Related]

  • 15. Retrospective Analysis of Intrathecal Drug Delivery: Outcomes, Efficacy, and Risk for Cancer-Related Pain at a High Volume Academic Medical Center.
    Sayed D, Monroe F, Orr WN, Phadnis M, Khan TW, Braun E, Manion S, Nicol A.
    Neuromodulation; 2018 Oct 08; 21(7):660-663. PubMed ID: 29446171
    [Abstract] [Full Text] [Related]

  • 16. Pain management, including intrathecal pumps.
    Smith TJ, Swainey C, Coyne PJ.
    Curr Oncol Rep; 2004 Jul 08; 6(4):291-6. PubMed ID: 15161583
    [Abstract] [Full Text] [Related]

  • 17. Intrathecal Drug Delivery Systems for Cancer Pain Control: Insights on Current Contemporary Practices in the US.
    Goel V, Kumar V, Blaes A, Gulati A.
    Neuromodulation; 2023 Aug 08; 26(6):1256-1262. PubMed ID: 37318432
    [Abstract] [Full Text] [Related]

  • 18. Prospective Observational Study of Patient-Controlled Intrathecal Analgesia: Impact on Cancer-Associated Symptoms, Breakthrough Pain Control, and Patient Satisfaction.
    Brogan SE, Winter NB, Okifuji A.
    Reg Anesth Pain Med; 2015 Aug 08; 40(4):369-75. PubMed ID: 25923819
    [Abstract] [Full Text] [Related]

  • 19. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
    Smith TJ, Coyne PJ.
    J Palliat Med; 2005 Aug 08; 8(4):736-42. PubMed ID: 16128647
    [Abstract] [Full Text] [Related]

  • 20. Long-term intrathecal opioid therapy with a patient-activated, implanted delivery system for the treatment of refractory cancer pain.
    Rauck RL, Cherry D, Boyer MF, Kosek P, Dunn J, Alo K.
    J Pain; 2003 Oct 08; 4(8):441-7. PubMed ID: 14622664
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.